The clinical utility of Ki‐67 in assessing tumor biology and aggressiveness in patients with appendiceal carcinoids

Authors:

Abstract
Background/Objective: To elucidate the correlation of Ki‐67 with tumor biology and survival in appendiceal carcinoid tumors.Method: A retrospective chart review conducted on 51 patients with appendiceal carcinoid tumors who underwent surgical intervention from 1991 to 2008. MIB‐1, an antibody of Ki‐67, was used to determine cell proliferation and correlated with clinical and histological parameters. MIB‐1 index was categorized according to the World Health Organization (WHO) classification.Result: Of the 51 patients, 32 had tumors 2 cm; and 16 with unspecified tumor size. Increased MIB proliferative index did not significantly correlate with increasing tumor size (P = 0.426). Twelve patients had metastatic disease on presentation: 9 had MIB‐1 index 15%. No significant correlation between MIB index and metastasis was demonstrated (P = 0.68). Median follow‐up was 40 months (range 10–183 months) with a 51% follow‐up rate. Seven mortalities and three recurrences presented in 26 patients. Assessment of survival demonstrated significantly decreased survival by increasing MIB index. Survival rate by MIB index was as follows: 15% was 67% (P = 0.02).Conclusion: Increased MIB index significantly correlated with decreased survival. No correlation was demonstrated by MIB index and tumor size or presentation with metastatic disease. J. Surg. Oncol. 2010;102:338–341.

This publication has 21 references indexed in Scilit: